Ball D, Mai G, Vinod S, Babington S, Ruben J, Kron T, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20:494–503.

Article  PubMed  Google Scholar 

Beauchesne P, Bernier V, Carnin C, Taillandier L, Djabri M, Martin L, et al. Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. Neuro-Oncol. 2010;12:595–602.

Article  PubMed  PubMed Central  Google Scholar 

Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non–small-cell lung cancer. J Clin Oncol. 2007;25:5557–61.

Article  PubMed  Google Scholar 

Chang J, Gandhidasan S, Finnigan R, Whalley D, Nair R, Herschtal A, et al. Stereotactic ablative body radiotherapy for the treatment of spinal oligometastases. Clin Oncol. 2017;29:e119–25.

Article  CAS  Google Scholar 

Dionisi F, Croci S, Giacomelli I, Cianchetti M, Caldara A, Bertolin M, et al. Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma. Acta Oncol. 2019;58:1238–45.

Article  CAS  PubMed  Google Scholar 

Ghaderi N, Jung J, Brüningk SC, Subramanian A, Nassour L, Peacock J. A century of fractionated radiotherapy: how mathematical oncology can break the rules. Int J Mol Sci. 2022;23:1316.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81–94.

Article  CAS  PubMed  Google Scholar 

Chew MT, Jones B, Hill M, Bradley D. Radiation, a two-edged sword: from untoward effects to fractionated radiotherapy. Radiat Phys Chem. 2021;178:108994.

Article  CAS  Google Scholar 

Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014;11:432–8.

Article  PubMed  Google Scholar 

Ajdari A, Niyazi M, Nicolay NH, Thieke C, Jeraj R, Bortfeld T. Towards optimal stopping in radiation therapy. Radiother Oncol. 2019;134:96–100.

Article  PubMed  Google Scholar 

Zhang H, Klareskog L, Matussek A, Pfister SM, Benson M. Translating genomic medicine to the clinic: challenges and opportunities. Genome Med. 2019;11:9.

Article  PubMed  PubMed Central  Google Scholar 

Blasiak A, Khong J, Kee T. CURATE. AI: optimizing personalized medicine with artificial intelligence. SLAS Technol. 2020;25:95–105.

Article  CAS  PubMed  Google Scholar 

Al-Shyoukh I, Yu F, Feng J, Yan K, Dubinett S, Ho C-M, et al. Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Syst Biol. 2011;5:88.

Article  PubMed  PubMed Central  Google Scholar 

Clemens DL, Lee B-Y, Silva A, Dillon BJ, Masleša-Galić S, Nava S, et al. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. PLoS One. 2019;14:e0215607.

Article  PubMed  PubMed Central  Google Scholar 

Rashid MBMA, Toh TB, Hooi L, Silva A, Zhang Y, Tan PF, et al. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Sci Transl Med. 2018;10:eaan0941.

Article  PubMed  Google Scholar 

Truong A, Tan LW, Chew KA, Villaraza S, Siongco P, Blasiak A, et al. Harnessing CURATE. AI for N‐of‐1 optimization analysis of combination therapy in hypertension patients: a retrospective case series (Adv. Therap. 10/2021). Adv Ther. 2021;4:2170030.

Article  Google Scholar 

Zarrinpar A, Silva A, Lee DK, Datta N, Ho CM, Ho, D. Phenotypic personalized medicine: mechanism-independent convergence into target serum tacrolimus levels for optimized liver transplant immunosuppression. American Transplant Congress. 2015 (abstract C264).

Tan SB, Senthil Kumar K, Gan TR, Tan LW, Truong AT, Blasiak A, et al. CURATE. AI—artificial intelligence‐derived personalized tacrolimus dosing for pediatric liver transplant: a retrospective study. Adv Ther. 2024;7:2300236

Ding X, Chang VH, Li Y, Li X, Xu H, Ho CM, et al. Harnessing an artificial intelligence platform to dynamically individualize combination therapy for treating colorectal carcinoma in a rat model. Adv Ther. 2020;3:1900127.

Article  Google Scholar 

Tsutsui H, Valamehr B, Hindoyan A, Qiao R, Ding X, Guo S, et al. An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nat Commun. 2011;2:167.

Article  PubMed  Google Scholar 

Wong PK, Yu F, Shahangian A, Cheng G, Sun R, Ho C-M. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc Natl Acad Sci. 2008;105:5105–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ho D, Ho CM, Zarrinpar A, Lee DK, Vite AM, Datta N. Phenotypic personalized medicine: adaptive optimization of patient-specific combination therapy. United States patent application US 15/558,983. 2019.

Zarrinpar A, Lee D-K, Silva A, Datta N, Kee T, Eriksen C, et al. Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. Sci Transl Med. 2016;8:333ra49–ra49.

Article  PubMed  Google Scholar 

Kim HJ, Lee J, Lee JG, Joo DJ, Kim MS. Clinical association between tacrolimus intra-patient variability and liver transplantation outcomes in patients with and without hepatocellular carcinoma. Sci Rep. 2022;12:16169.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pantuck AJ, Lee DK, Kee T, Wang P, Lakhotia S, Silverman MH, et al. Modulating BET bromodomain inhibitor ZEN‐3694 and enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE. AI, an artificial intelligence platform. Adv Ther. 2018;1:1800104.

Article  Google Scholar 

Blasiak A, Truong AT, Remus A, Hooi L, Seah SG, Wang P, et al. The IDentif. AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens. NPJ Digit Med. 2022;5:83.

Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. npj Digit Med. 2020;3:17.

Article  PubMed  PubMed Central  Google Scholar 

Chua IS, Gaziel‐Yablowitz M, Korach ZT, Kehl KL, Levitan NA, Arriaga YE, et al. Artificial intelligence in oncology: path to implementation. Cancer Med. 2021;10:4138–49.

Article  PubMed  PubMed Central  Google Scholar 

Chaudhuri A, Lovejoy A, Chabon J, Newman A, Stehr H, Merriott D, et al. Circulating tumor DNA analysis during radiation therapy for localized lung cancer predicts treatment outcome. Int J Radiat Oncol, Biol, Phys. 2017;99:S1–2.

Article  Google Scholar 

Chan S-K, Chan S-Y, Choi HC-W, Tong C-C, Lam K-O, Kwong DL-W, et al. Prognostication of half-life clearance of plasma EBV DNA in previously untreated non-metastatic nasopharyngeal carcinoma treated with radical intensity-modulated radiation therapy. Front Oncol. 2020;10:1417.

Article  PubMed  PubMed Central  Google Scholar 

Chaudhuri AA, Binkley MS, Osmundson EC, Alizadeh AA, Diehn M. editors. Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA. Seminars in radiation oncology; 2015: Elsevier.

Lv J, Wu C, Li J, Chen F, He S, He Q, et al. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics. BMC Med. 2022;20:268.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noguchi T, Iwahashi N, Sakai K, Matsuda K, Matsukawa H, Toujima S, et al. Comprehensive gene mutation profiling of circulating tumor DNA in ovarian cancer: its pathological and prognostic impact. Cancers. 2020;12:3382.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song Y, Hu C, Xie Z, Wu L, Zhu Z, Rao C, et al. Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Transl Lung Cancer Res. 2020;9:269.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han K, Leung E, Barbera L, Barnes E, Croke J, Di Grappa MA, et al. Circulating human papillomavirus DNA as a biomarker of response in patients with locally advanced cervical cancer treated with definitive chemoradiation. JCO Precis Oncol. 2018;2:1–8.

Article  PubMed  Google Scholar 

Lin J-C, Wang W-Y, Chen KY, Wei Y-H, Liang W-M, Jan J-S, et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N. Engl J Med. 2004;350:2461–70.

Article  CAS  PubMed  Google Scholar 

Symonds EL, Pedersen SK, Murray D, Byrne SE, Roy A, Karapetis C, et al. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. Cancer. 2020;126:1460–9.

Article  CAS  PubMed  Google Scholar 

Ostheimer C, Mäurer M, Ebert N, Schmitt D, Krug D, Baumann R, et al. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. Strahlentherapie und Onkol. 2021;197:385–95.

Article  CAS  Google Scholar 

Vandewinckele L, Claessens M, Dinkla A, Brouwer C, Crijns W, Verellen D, et al. Overview of artificial intelligence-based applications in radiotherapy: recommendations for implementation and quality assurance. Radiother Oncol. 2020;153:55–66.

Article  PubMed  Google Scholar 

Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, et al. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. Br J Cancer. 2017;117:717–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mkrtchyan GV, Veviorskiy A, Izumchenko E, Shneyderman A, Pun FW, Ozerov IV, et al. High-confidence cancer patient stratification through multiomics investigation of DNA repair disorders. Cell Death Dis. 2022;13:999.

Article  CAS